Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|August 1, 2025
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancerKeisuke Miwa, Reina Kawasaki, Mototsugu Shimokawa, et al.
Therapeutic Advances in Medical Oncology|February 24, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, et al.
BMC Cancer|May 27, 2026
Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: a multicenter, prospective cohort study (NAPOLEON-2)Wataru Yoshioka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Scientific Reports|January 27, 2025
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, et al.
Therapeutic Advances in Medical Oncology|November 21, 2025
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 studyTomomi Koike, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.
International Journal of Cancer|August 1, 2025
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acidTomonori Araki, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2018
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched studyAkitaka Makiyama, Kenji Kunieda, Masaaki Noguchi, et al.
Scientific Reports|July 23, 2024
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxelTaro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, et al.
Scientific Reports|May 30, 2024
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancerTomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, et al.
Oncology|October 20, 2024
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 StudiesTomonori Araki, Machiko Kawahira, Mototsugu Shimokawa, et al.
Pageof 5